ASH 2020 | What were the CLL highlights at ASH 2020?
Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, shares which ASH 2020 chronic lymphocytic leukemia (CLL) presentations were highlights for her. These include encouraging data from trials of lisocabtagene maraleucel (lisa-cel), as a single agent and in combination with ibrutinib; significant efficacy findings in the UNITY-CLL trial (NCT02612311) of umbralisib plus ublituximab, representing the first Phase III study of PI3Ks vs chemoimmunotherapy in CLL; and updated results from the CAPTIVATE (NCT02910583) trial of ibrutinib and venetoclax in the frontline setting. A variety of novel agents also came to the fore at ASH 2020, such as LOXO-305, a reversible highly selective BTK inhibitor. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
